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A B S T R A C T
Testicular germ cell tumors are the most common solid organ malignancy in young adult men. The presence of non-pulmonary visceral
metastasis is an independent factor that places such patients into the higher risk group. Hepatic hemangiomas are the most common
tumors of the liver and are entirely benign. Overlap between these entities may occur, particularly when metastases are hypervascular.
We describe a case of a 27-year-old man with a testicular germ cell tumor and a nodule in the right hepatic lobe suggestive of hemangioma.
After three cycles of chemotherapy, a size reduction in the hepatic nodule was confirmed, and this lesion was removed. Pathology revealed a
fibrosing hemangioma.
In this case report, the authors discuss the possible mechanisms for the hemangioma chemotherapy response.
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INTRODUCTION
Testicular germ cell tumors are the most common solid
organ malignancy in young adult men. Of testicular tumors,
40% are seminomas and 60% non-seminomas.1 Non-
seminoma is the more clinically aggressive tumor. The
presence of non-pulmonary visceral metastasis is an inde-
pendent factor that places such patients into the higher risk
group.2 Management of patients with non-pulmonary visceral
metastasis from non-seminoma includes full schedule che-
motherapy with bleomycin, etoposide, and cisplatin (BEP) for
four cycles (standard), given as 5-day schedule, and resection
of any residual radiographic abnormality if technically
feasible.1
Hepatic hemangiomas are the most common tumors of the
liver and are entirely benign.3 Treatment is unnecessary
unless their expansion causes symptoms. Liver metastases
and hemangiomas may be distinguished with imaging
modalities, including magnetic resonance imaging (MRI),
on the basis of lesion morphology and T2 measurements.4
However, overlap between these entities may occur, particu-
larly when metastases are hypervascular.5
CASE REPORT
A 27-year-old man detected a mass in testicular auto-
examination. Ultrasound confirmed testicular mass was
suspicious for malignancy. Alpha-fetoprotein (AFP) and
human chorionic gonadotropin (HCG) levels were 33 ng/mL
and 16 mIU/mL, respectively. Thoracic, abdominal, and pelvic
computed tomography (CT) showed two micronodules
(5 mm) in the anterior segment of the left lung lobe and a
27-mm nodule in the right hepatic lobe suggestive of
hemangioma, hypothesis that was corroborated by MRI
(Figure 1).
The patient was submitted to radical orchiectomy. Pathology
revealed a 3-cm germ cell tumor with teratocarcinoma and
embrionary carcinoma components (Figure 2). After orch-
iectomy, an elevation of tumor markers was registered (AFP:
428.2 mg/dL, HCG: 46.7 U/L), and the patient received primary
chemotherapy. Because hepatic lesion was assumed a heman-
gioma, the tumor was classified as IS, and three cycles of BEP
were given. With chemotherapy, the tumor markers normal-
ized, as expected. The reevaluation CT scan showed a size
reduction of the hepatic nodule (from 27 to 18 mm)
(Figure 3). With these unexpected findings, the multidisci-
plinary group decision was to perform hepatic lesion excision.
Pathology revealed a fibrosing hemangioma (Figure 4).
DISCUSSION
This clinical case presented a diagnosis and decision-
making challenge. Even though the hepatic lesion had a
low pretest probability of being malignant, if this lesion did
represent metastatic disease, the treatment plan and prog-
nosis would be different. The shrinking of the hepatic lesion
raised the possibility for the lesion to be metastatic.
Hepatic hemangioma is the most common liver tumor.
Hemangiomas are often solitary, but multiple lesions may be
present in both the right and left lobes of the liver in up to
40% of the patients.6 The point prevalence of hepatic
hemangiomas may reach 20%.7 This observation is confirmed
by the increasing recognition of hemangiomas in asympto-
matic patients undergoing radiologic imaging tests of the
abdomen for other reasons. However, hepatic hemangioma
can be confirmed in more than 90% of patients by a CT scan
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or an MRI.8 Other studies showed that the diagnosis of
hepatic hemangioma remained dubious in nearly 10% of the
patients using three different imaging modalities (including
ultrasound, CT, MRI, scintigraphy, and angiography).9 Mi-
croscopically, the tumor is composed of cavernous vascular
spaces of varying sizes lined by a single layer of flat
endothelium and filled with blood. The vascular compart-
ments are separated by thin fibrous septae and may contain
thrombi.10 The etiology of hepatic hemangiomas is
incompletely understood. They are considered to be vascular
malformations of congenital origin that enlarge by ectasia
rather than by hyperplasia or hypertrophy. Hormonal influ-
ence over tumor growth is suggested by enlargement during
pregnancy and estrogen and progesterone therapy and
regression after withdrawal of therapy.8,1113 Vascular en-
dothelial growth factor (VEGF) is recognized as an essential
regulator of normal and abnormal blood vessel growth.14 It is
postulated that higher expression of VEGF and angiopoietins
leads to increased angiogenic activity in cavernous heman-
gioma endothelial cells.15 Stromal cells cultured from surgi-
cally removed life-threatening hemangiomas released an
endothelial cell mitogen in vitro that was indistinguishable
from VEGF, and systemic injections of neutralizing anti-
VEGF antibodies inhibited the angiogenic response in nude
mice grafted with neonatal hemangioma cells.16 Bevacizumab
is a recombinant monoclonal antibody against VEGF and has
been shown to be effective in the hemangioma size reduc-
tion.15 Another case report, very similar to ours, reported a
patient with testis cancer with a hepatic hemangioma that
responded partially to systemic chemotherapy.17 Our hypoth-
esis is that the decreased size of the hemangioma in our
patient could have been a result of chemotherapy, perhaps
through antiangiogenic mechanisms.18
CONCLUSION
Our case report shows that, in the absence of definitive
imaging criteria, a chemotherapy-induced response of he-
mangioma can mimic a chemotherapy response of metastatic
Figure 1. Hepatic MRI: hepatic lesion with hypersinal in T2 ponderation,
corresponding to a provable fibrosing hemangioma.
Figure 2. Germ cell tumor: teratoma (*) and embrionary carcinoma
components (#).
Figure 4. Fibrosing hepatic hemangioma.
Figure 3. Downsizing of hepatic lesion during chemotherapy, from 27 mm (left image) to 18 mm (right image).
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disease. Differentiating these two entities solely on clinical
grounds can become a huge challenge, if not impossible.
Disclosure: The authors declare no conflict of interest.
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